Epilepsy Therapeutic Market in APAC 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	156 Pages	TechNavio	January, 2024	INF18436674

Best Price Guarantee
Price	from $2,500
Length	156 Pages
Publisher	TechNavio
Published Date	January, 2024
SKU	INF18436674

Epilepsy Therapeutic Market In APAC 2024-2028

The epilepsy therapeutic market in APAC is forecasted to grow by USD 449.35 mn during 2023-2028, accelerating at a CAGR of 4.19% during the forecast period. The report on the epilepsy therapeutic market in APAC provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high unmet need for disease-modifying treatment, increase in patient population having epilepsy, and rising awareness regarding epilepsy.

Technavio's epilepsy therapeutic market in APAC is segmented as below:

By Distribution Channel

Hospital pharmacy
Retail pharmacy
Online pharmacy

By Product

First-generation epilepsy therapeutics
Second-generation epilepsy therapeutics
Third-generation epilepsy therapeutics

This study identifies the reformation of marketed epilepsy drugs as one of the prime reasons driving the epilepsy therapeutic market in APAC growth during the next few years. Also, the emergence of new-generation AEDS and AEDS with novel mechanism action will lead to sizable demand in the market.

The report on the epilepsy therapeutic market in APAC covers the following areas:

Epilepsy therapeutic market in APAC sizing
Epilepsy therapeutic market in APAC forecast
Epilepsy therapeutic market in APAC industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epilepsy therapeutic market in APAC vendors that include Alkem Laboratories Ltd., Bausch Health Companies Inc., BIAL, Dr Reddys Laboratories Ltd., Eisai Co. Ltd., H Lundbeck AS, Johnson and Johnson, Novartis AG, Pfizer Inc., Sanofi SA, SK Inc., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and GlaxoSmithKline Plc. Also, the epilepsy therapeutic market in APAC analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Country Market Characteristics; Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape; Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel; Exhibit 06: Executive Summary - Chart on Market Segmentation by Product; Exhibit 07: Executive Summary - Chart on Incremental Growth; Exhibit 08: Executive Summary - Data Table on Incremental Growth; Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 10: Parent market; Exhibit 11: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 12: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 13: Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Exhibit 14: Chart on APAC - Market size and forecast 2023-2028 ($ million); Exhibit 15: Data Table on Regional - Market size and forecast 2023-2028 ($ million); Exhibit 16: Chart on APAC: Year-over-year growth 2023-2028 (%); Exhibit 17: Data Table on Regional - Market size and forecast 2023-2028 ($ million)
4 Historic Market Size: 4.1 epilepsy therapeutics market in APAC 2018 - 2022; Exhibit 18: Historic Market Size - Data Table on epilepsy therapeutics market in APAC 2018 - 2022 ($ million); 4.2 Distribution Channel Segment Analysis 2018 - 2022; Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million); 4.3 Product Segment Analysis 2018 - 2022; Exhibit 20: Historic Market Size - Product Segment 2018 - 2022 ($ million); 4.4 Geography Segment Analysis 2018 - 2022; Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 22: Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Exhibit 23: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Exhibit 24: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Exhibit 25: Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Exhibit 26: Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Exhibit 27: Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Exhibit 28: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Distribution Channel: 6.1 Market segments; Exhibit 29: Chart on Distribution Channel - Market share 2023-2028 (%); Exhibit 30: Data Table on Distribution Channel - Market share 2023-2028 (%); 6.2 Comparison by Distribution Channel; Exhibit 31: Chart on Comparison by Distribution Channel; Exhibit 32: Data Table on Comparison by Distribution Channel; 6.3 Hospital pharmacy - Market size and forecast 2023-2028; Exhibit 33: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million); Exhibit 34: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million); Exhibit 35: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%); Exhibit 36: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%); 6.4 Retail pharmacy - Market size and forecast 2023-2028; Exhibit 37: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million); Exhibit 38: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million); Exhibit 39: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%); Exhibit 40: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%); 6.5 Online pharmacy - Market size and forecast 2023-2028; Exhibit 41: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million); Exhibit 42: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million); Exhibit 43: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%); Exhibit 44: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%); 6.6 Market opportunity by Distribution Channel; Exhibit 45: Market opportunity by Distribution Channel ($ million); Exhibit 46: Data Table on Market opportunity by Distribution Channel ($ million)
7 Market Segmentation by Product: 7.1 Market segments; Exhibit 47: Chart on Product - Market share 2023-2028 (%); Exhibit 48: Data Table on Product - Market share 2023-2028 (%); 7.2 Comparison by Product; Exhibit 49: Chart on Comparison by Product; Exhibit 50: Data Table on Comparison by Product; 7.3 First-generation epilepsy therapeutics - Market size and forecast 2023-2028; Exhibit 51: Chart on First-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibit 52: Data Table on First-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibit 53: Chart on First-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); Exhibit 54: Data Table on First-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); 7.4 Second-generation epilepsy therapeutics - Market size and forecast 2023-2028; Exhibit 55: Chart on Second-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibit 56: Data Table on Second-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibit 57: Chart on Second-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); Exhibit 58: Data Table on Second-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); 7.5 Third-generation epilepsy therapeutics - Market size and forecast 2023-2028; Exhibit 59: Chart on Third-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibit 60: Data Table on Third-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibit 61: Chart on Third-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); Exhibit 62: Data Table on Third-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); 7.6 Market opportunity by Product; Exhibit 63: Market opportunity by Product ($ million); Exhibit 64: Data Table on Market opportunity by Product ($ million)
8 Customer Landscape: 8.1 Customer landscape overview; Exhibit 65: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Exhibit 66: Chart on Market share By Geographical Landscape - 2023-2028 (%); Exhibit 67: Data Table on Market share By Geographical Landscape - 2023-2028 (%); 9.2 Geographic comparison; Exhibit 68: Chart on Geographic comparison; Exhibit 69: Data Table on Geographic comparison; 9.3 China - Market size and forecast 2023-2028; Exhibit 70: Chart on China - Market size and forecast 2023-2028 ($ million); Exhibit 71: Data Table on China - Market size and forecast 2023-2028 ($ million); Exhibit 72: Chart on China - Year-over-year growth 2023-2028 (%); Exhibit 73: Data Table on China - Year-over-year growth 2023-2028 (%); 9.4 Japan - Market size and forecast 2023-2028; Exhibit 74: Chart on Japan - Market size and forecast 2023-2028 ($ million); Exhibit 75: Data Table on Japan - Market size and forecast 2023-2028 ($ million); Exhibit 76: Chart on Japan - Year-over-year growth 2023-2028 (%); Exhibit 77: Data Table on Japan - Year-over-year growth 2023-2028 (%); 9.5 India - Market size and forecast 2023-2028; Exhibit 78: Chart on India - Market size and forecast 2023-2028 ($ million); Exhibit 79: Data Table on India - Market size and forecast 2023-2028 ($ million); Exhibit 80: Chart on India - Year-over-year growth 2023-2028 (%); Exhibit 81: Data Table on India - Year-over-year growth 2023-2028 (%); 9.6 Australia - Market size and forecast 2023-2028; Exhibit 82: Chart on Australia - Market size and forecast 2023-2028 ($ million); Exhibit 83: Data Table on Australia - Market size and forecast 2023-2028 ($ million); Exhibit 84: Chart on Australia - Year-over-year growth 2023-2028 (%); Exhibit 85: Data Table on Australia - Year-over-year growth 2023-2028 (%); 9.7 Rest of APAC - Market size and forecast 2023-2028; Exhibit 86: Chart on Rest of APAC - Market size and forecast 2023-2028 ($ million); Exhibit 87: Data Table on Rest of APAC - Market size and forecast 2023-2028 ($ million); Exhibit 88: Chart on Rest of APAC - Year-over-year growth 2023-2028 (%); Exhibit 89: Data Table on Rest of APAC - Year-over-year growth 2023-2028 (%); 9.8 Market opportunity By Geographical Landscape; Exhibit 90: Market opportunity By Geographical Landscape ($ million); Exhibit 91: Data Table on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 92: Impact of drivers and challenges in 2023 and 2028; 10.4 Market trends
11 Vendor Landscape: 11.1 Overview; 11.2 Vendor landscape; Exhibit 93: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 94: Overview on factors of disruption; 11.4 Industry risks; Exhibit 95: Impact of key risks on business
12 Vendor Analysis: 12.1 Vendors covered; Exhibit 96: Vendors covered; 12.2 Market positioning of vendors; Exhibit 97: Matrix on vendor position and classification; 12.3 Bausch Health Companies Inc.; Exhibit 98: Bausch Health Companies Inc. - Overview; Exhibit 99: Bausch Health Companies Inc. - Business segments; Exhibit 100: Bausch Health Companies Inc. - Key news; Exhibit 101: Bausch Health Companies Inc. - Key offerings; Exhibit 102: Bausch Health Companies Inc. - Segment focus; 12.4 BIAL; Exhibit 103: BIAL - Overview; Exhibit 104: BIAL - Product / Service; Exhibit 105: BIAL - Key offerings; 12.5 Dr Reddys Laboratories Ltd.; Exhibit 106: Dr Reddys Laboratories Ltd. - Overview; Exhibit 107: Dr Reddys Laboratories Ltd. - Business segments; Exhibit 108: Dr Reddys Laboratories Ltd. - Key offerings; Exhibit 109: Dr Reddys Laboratories Ltd. - Segment focus; 12.6 Eisai Co. Ltd.; Exhibit 110: Eisai Co. Ltd. - Overview; Exhibit 111: Eisai Co. Ltd. - Business segments; Exhibit 112: Eisai Co. Ltd. - Key offerings; Exhibit 113: Eisai Co. Ltd. - Segment focus; 12.7 GlaxoSmithKline Plc; Exhibit 114: GlaxoSmithKline Plc - Overview; Exhibit 115: GlaxoSmithKline Plc - Business segments; Exhibit 116: GlaxoSmithKline Plc - Key news; Exhibit 117: GlaxoSmithKline Plc - Key offerings; Exhibit 118: GlaxoSmithKline Plc - Segment focus; 12.8 H Lundbeck AS; Exhibit 119: H Lundbeck AS - Overview; Exhibit 120: H Lundbeck AS - Product / Service; Exhibit 121: H Lundbeck AS - Key offerings; 12.9 Johnson and Johnson; Exhibit 122: Johnson and Johnson - Overview; Exhibit 123: Johnson and Johnson - Business segments; Exhibit 124: Johnson and Johnson - Key news; Exhibit 125: Johnson and Johnson - Key offerings; Exhibit 126: Johnson and Johnson - Segment focus; 12.10 Novartis AG; Exhibit 127: Novartis AG - Overview; Exhibit 128: Novartis AG - Business segments; Exhibit 129: Novartis AG - Key offerings; Exhibit 130: Novartis AG - Segment focus; 12.11 Pfizer Inc.; Exhibit 131: Pfizer Inc. - Overview; Exhibit 132: Pfizer Inc. - Product / Service; Exhibit 133: Pfizer Inc. - Key news; Exhibit 134: Pfizer Inc. - Key offerings; 12.12 Sanofi SA; Exhibit 135: Sanofi SA - Overview; Exhibit 136: Sanofi SA - Business segments; Exhibit 137: Sanofi SA - Key news; Exhibit 138: Sanofi SA - Key offerings; Exhibit 139: Sanofi SA - Segment focus; 12.13 SK Inc.; Exhibit 140: SK Inc. - Overview; Exhibit 141: SK Inc. - Product / Service; Exhibit 142: SK Inc. - Key offerings; 12.14 Sumitomo Pharma Co. Ltd.; Exhibit 143: Sumitomo Pharma Co. Ltd. - Overview; Exhibit 144: Sumitomo Pharma Co. Ltd. - Business segments; Exhibit 145: Sumitomo Pharma Co. Ltd. - Key offerings; Exhibit 146: Sumitomo Pharma Co. Ltd. - Segment focus; 12.15 Sun Pharmaceutical Industries Ltd.; Exhibit 147: Sun Pharmaceutical Industries Ltd. - Overview; Exhibit 148: Sun Pharmaceutical Industries Ltd. - Product / Service; Exhibit 149: Sun Pharmaceutical Industries Ltd. - Key offerings; 12.16 Teva Pharmaceutical Industries Ltd.; Exhibit 150: Teva Pharmaceutical Industries Ltd. - Overview; Exhibit 151: Teva Pharmaceutical Industries Ltd. - Business segments; Exhibit 152: Teva Pharmaceutical Industries Ltd. - Key news; Exhibit 153: Teva Pharmaceutical Industries Ltd. - Key offerings; Exhibit 154: Teva Pharmaceutical Industries Ltd. - Segment focus; 12.17 UCB SA; Exhibit 155: UCB SA - Overview; Exhibit 156: UCB SA - Product / Service; Exhibit 157: UCB SA - Key offerings
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 158: Inclusions checklist; Exhibit 159: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 160: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 161: Research methodology; Exhibit 162: Validation techniques employed for market sizing; Exhibit 163: Information sources; 13.5 List of abbreviations; Exhibit 164: List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Country Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by Distribution Channel; Exhibits6: Executive Summary - Chart on Market Segmentation by Product; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Vendor Market Positioning; Exhibits10: Parent market; Exhibits11: Market Characteristics; Exhibits12: Offerings of vendors included in the market definition; Exhibits13: Market segments; Exhibits14: Chart on APAC - Market size and forecast 2023-2028 ($ million); Exhibits15: Data Table on Regional - Market size and forecast 2023-2028 ($ million); Exhibits16: Chart on APAC: Year-over-year growth 2023-2028 (%); Exhibits17: Data Table on Regional - Market size and forecast 2023-2028 ($ million); Exhibits18: Historic Market Size - Data Table on epilepsy therapeutics market in APAC 2018 - 2022 ($ million); Exhibits19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million); Exhibits20: Historic Market Size - Product Segment 2018 - 2022 ($ million); Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million); Exhibits22: Five forces analysis - Comparison between 2023 and 2028; Exhibits23: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits24: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits25: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits26: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits27: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits28: Chart on Market condition - Five forces 2023 and 2028; Exhibits29: Chart on Distribution Channel - Market share 2023-2028 (%); Exhibits30: Data Table on Distribution Channel - Market share 2023-2028 (%); Exhibits31: Chart on Comparison by Distribution Channel; Exhibits32: Data Table on Comparison by Distribution Channel; Exhibits33: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million); Exhibits34: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million); Exhibits35: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%); Exhibits36: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%); Exhibits37: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million); Exhibits38: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million); Exhibits39: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%); Exhibits40: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%); Exhibits41: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million); Exhibits42: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million); Exhibits43: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%); Exhibits44: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%); Exhibits45: Market opportunity by Distribution Channel ($ million); Exhibits46: Data Table on Market opportunity by Distribution Channel ($ million); Exhibits47: Chart on Product - Market share 2023-2028 (%); Exhibits48: Data Table on Product - Market share 2023-2028 (%); Exhibits49: Chart on Comparison by Product; Exhibits50: Data Table on Comparison by Product; Exhibits51: Chart on First-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibits52: Data Table on First-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibits53: Chart on First-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); Exhibits54: Data Table on First-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); Exhibits55: Chart on Second-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibits56: Data Table on Second-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibits57: Chart on Second-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); Exhibits58: Data Table on Second-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); Exhibits59: Chart on Third-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibits60: Data Table on Third-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million); Exhibits61: Chart on Third-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); Exhibits62: Data Table on Third-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%); Exhibits63: Market opportunity by Product ($ million); Exhibits64: Data Table on Market opportunity by Product ($ million); Exhibits65: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits66: Chart on Market share By Geographical Landscape - 2023-2028 (%); Exhibits67: Data Table on Market share By Geographical Landscape - 2023-2028 (%); Exhibits68: Chart on Geographic comparison; Exhibits69: Data Table on Geographic comparison; Exhibits70: Chart on China - Market size and forecast 2023-2028 ($ million); Exhibits71: Data Table on China - Market size and forecast 2023-2028 ($ million); Exhibits72: Chart on China - Year-over-year growth 2023-2028 (%); Exhibits73: Data Table on China - Year-over-year growth 2023-2028 (%); Exhibits74: Chart on Japan - Market size and forecast 2023-2028 ($ million); Exhibits75: Data Table on Japan - Market size and forecast 2023-2028 ($ million); Exhibits76: Chart on Japan - Year-over-year growth 2023-2028 (%); Exhibits77: Data Table on Japan - Year-over-year growth 2023-2028 (%); Exhibits78: Chart on India - Market size and forecast 2023-2028 ($ million); Exhibits79: Data Table on India - Market size and forecast 2023-2028 ($ million); Exhibits80: Chart on India - Year-over-year growth 2023-2028 (%); Exhibits81: Data Table on India - Year-over-year growth 2023-2028 (%); Exhibits82: Chart on Australia - Market size and forecast 2023-2028 ($ million); Exhibits83: Data Table on Australia - Market size and forecast 2023-2028 ($ million); Exhibits84: Chart on Australia - Year-over-year growth 2023-2028 (%); Exhibits85: Data Table on Australia - Year-over-year growth 2023-2028 (%); Exhibits86: Chart on Rest of APAC - Market size and forecast 2023-2028 ($ million); Exhibits87: Data Table on Rest of APAC - Market size and forecast 2023-2028 ($ million); Exhibits88: Chart on Rest of APAC - Year-over-year growth 2023-2028 (%); Exhibits89: Data Table on Rest of APAC - Year-over-year growth 2023-2028 (%); Exhibits90: Market opportunity By Geographical Landscape ($ million); Exhibits91: Data Table on Market opportunity By Geographical Landscape ($ million); Exhibits92: Impact of drivers and challenges in 2023 and 2028; Exhibits93: Overview on Criticality of inputs and Factors of differentiation; Exhibits94: Overview on factors of disruption; Exhibits95: Impact of key risks on business; Exhibits96: Vendors covered; Exhibits97: Matrix on vendor position and classification; Exhibits98: Bausch Health Companies Inc. - Overview; Exhibits99: Bausch Health Companies Inc. - Business segments; Exhibits100: Bausch Health Companies Inc. - Key news; Exhibits101: Bausch Health Companies Inc. - Key offerings; Exhibits102: Bausch Health Companies Inc. - Segment focus; Exhibits103: BIAL - Overview; Exhibits104: BIAL - Product / Service; Exhibits105: BIAL - Key offerings; Exhibits106: Dr Reddys Laboratories Ltd. - Overview; Exhibits107: Dr Reddys Laboratories Ltd. - Business segments; Exhibits108: Dr Reddys Laboratories Ltd. - Key offerings; Exhibits109: Dr Reddys Laboratories Ltd. - Segment focus; Exhibits110: Eisai Co. Ltd. - Overview; Exhibits111: Eisai Co. Ltd. - Business segments; Exhibits112: Eisai Co. Ltd. - Key offerings; Exhibits113: Eisai Co. Ltd. - Segment focus; Exhibits114: GlaxoSmithKline Plc - Overview; Exhibits115: GlaxoSmithKline Plc - Business segments; Exhibits116: GlaxoSmithKline Plc - Key news; Exhibits117: GlaxoSmithKline Plc - Key offerings; Exhibits118: GlaxoSmithKline Plc - Segment focus; Exhibits119: H Lundbeck AS - Overview; Exhibits120: H Lundbeck AS - Product / Service; Exhibits121: H Lundbeck AS - Key offerings; Exhibits122: Johnson and Johnson - Overview; Exhibits123: Johnson and Johnson - Business segments; Exhibits124: Johnson and Johnson - Key news; Exhibits125: Johnson and Johnson - Key offerings; Exhibits126: Johnson and Johnson - Segment focus; Exhibits127: Novartis AG - Overview; Exhibits128: Novartis AG - Business segments; Exhibits129: Novartis AG - Key offerings; Exhibits130: Novartis AG - Segment focus; Exhibits131: Pfizer Inc. - Overview; Exhibits132: Pfizer Inc. - Product / Service; Exhibits133: Pfizer Inc. - Key news; Exhibits134: Pfizer Inc. - Key offerings; Exhibits135: Sanofi SA - Overview; Exhibits136: Sanofi SA - Business segments; Exhibits137: Sanofi SA - Key news; Exhibits138: Sanofi SA - Key offerings; Exhibits139: Sanofi SA - Segment focus; Exhibits140: SK Inc. - Overview; Exhibits141: SK Inc. - Product / Service; Exhibits142: SK Inc. - Key offerings; Exhibits143: Sumitomo Pharma Co. Ltd. - Overview; Exhibits144: Sumitomo Pharma Co. Ltd. - Business segments; Exhibits145: Sumitomo Pharma Co. Ltd. - Key offerings; Exhibits146: Sumitomo Pharma Co. Ltd. - Segment focus; Exhibits147: Sun Pharmaceutical Industries Ltd. - Overview; Exhibits148: Sun Pharmaceutical Industries Ltd. - Product / Service; Exhibits149: Sun Pharmaceutical Industries Ltd. - Key offerings; Exhibits150: Teva Pharmaceutical Industries Ltd. - Overview; Exhibits151: Teva Pharmaceutical Industries Ltd. - Business segments; Exhibits152: Teva Pharmaceutical Industries Ltd. - Key news; Exhibits153: Teva Pharmaceutical Industries Ltd. - Key offerings; Exhibits154: Teva Pharmaceutical Industries Ltd. - Segment focus; Exhibits155: UCB SA - Overview; Exhibits156: UCB SA - Product / Service; Exhibits157: UCB SA - Key offerings; Exhibits158: Inclusions checklist; Exhibits159: Exclusions checklist; Exhibits160: Currency conversion rates for US$; Exhibits161: Research methodology; Exhibits162: Validation techniques employed for market sizing; Exhibits163: Information sources; Exhibits164: List of abbreviations